GSK Future Growth

Future criteria checks 4/6

GSK is forecast to grow earnings and revenue by 14.3% and 4.6% per annum respectively. EPS is expected to grow by 14.2% per annum. Return on equity is forecast to be 39% in 3 years.

Key information

14.3%

Earnings growth rate

14.2%

EPS growth rate

Pharmaceuticals earnings growth	16.2%
Revenue growth rate	4.6%
Future return on equity	39.0%
Analyst coverage	Good
Last updated	12 Sep 2024

Recent future growth updates

No updates

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

Apr 19

GSK's (LON:GSK) Solid Earnings Are Supported By Other Strong Factors

Feb 07

Earnings and Revenue Growth Forecasts

LSE:GSK - Analysts future estimates and past financials data (GBP Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	35,399	7,158	7,613	10,012	18
12/31/2025	33,391	6,442	6,973	9,161	20
12/31/2024	31,639	5,149	5,364	7,974	20
6/30/2024	31,446	4,033	5,222	7,479	N/A
3/31/2024	30,740	4,484	5,330	7,673	N/A
12/31/2023	30,328	4,928	4,436	6,768	N/A
9/30/2023	29,652	6,078	3,247	5,477	N/A
6/30/2023	29,334	5,373	2,486	4,586	N/A
3/31/2023	29,085	4,455	2,892	4,914	N/A
12/31/2022	29,324	4,461	5,341	7,403	N/A
9/30/2022	29,024	3,387	7,620	9,265	N/A
6/30/2022	27,822	3,505	8,073	10,506	N/A
3/31/2022	26,731	4,013	7,611	10,163	N/A
12/31/2021	24,696	3,316	5,939	7,952	N/A
9/30/2021	26,359	3,567	6,064	8,040	N/A
6/30/2021	28,378	3,934	4,871	6,339	N/A
3/31/2021	30,164	4,983	7,028	7,807	N/A
12/31/2020	24,354	4,873	6,839	8,441	N/A
9/30/2020	34,259	6,371	6,833	8,039	N/A
6/30/2020	34,998	6,679	8,751	9,693	N/A
3/31/2020	35,183	5,380	6,628	8,322	N/A
12/31/2019	33,754	4,645	6,261	8,020	N/A
9/30/2019	33,052	4,561	6,832	8,686	N/A
6/30/2019	31,759	4,427	6,488	8,248	N/A
3/31/2019	31,260	3,904	6,735	8,221	N/A
12/31/2018	30,821	3,623	6,881	8,421	N/A
9/30/2018	30,263	1,862	5,521	7,171	N/A
6/30/2018	30,014	1,656	5,140	6,991	N/A
3/31/2018	30,024	1,035	N/A	6,637	N/A
12/31/2017	30,186	1,532	N/A	6,918	N/A
9/30/2017	30,133	2,335	N/A	7,040	N/A
6/30/2017	29,832	1,931	N/A	6,910	N/A
3/31/2017	29,044	1,676	N/A	7,138	N/A
12/31/2016	27,889	912	N/A	6,497	N/A
9/30/2016	26,589	301	N/A	5,007	N/A
6/30/2016	25,174	31	N/A	3,721	N/A
3/31/2016	24,530	615	N/A	2,702	N/A
12/31/2015	23,923	8,422	N/A	2,569	N/A
9/30/2015	23,823	9,809	N/A	3,278	N/A
6/30/2015	23,342	9,672	N/A	4,070	N/A
3/31/2015	23,015	10,177	N/A	4,619	N/A
12/31/2014	23,006	2,756	N/A	5,176	N/A
9/30/2014	23,726	4,184	N/A	5,153	N/A
6/30/2014	24,590	4,752	N/A	5,957	N/A
3/31/2014	25,647	5,143	N/A	6,902	N/A
12/31/2013	26,505	5,436	N/A	7,222	N/A
9/30/2013	26,401	3,823	N/A	6,949	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GSK's forecast earnings growth (14.3% per year) is above the savings rate (1.9%).

Earnings vs Market: GSK's earnings (14.3% per year) are forecast to grow faster than the UK market (14.2% per year).

High Growth Earnings: GSK's earnings are forecast to grow, but not significantly.

Revenue vs Market: GSK's revenue (4.6% per year) is forecast to grow faster than the UK market (3.7% per year).

High Growth Revenue: GSK's revenue (4.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GSK's Return on Equity is forecast to be high in 3 years time (39%)

GSK Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Recent updates

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

Does GSK (LON:GSK) Have A Healthy Balance Sheet?

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Second quarter dividend of UK£0.15 announced

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

GSK (LON:GSK) Will Pay A Dividend Of £0.15

First quarter dividend of UK£0.15 announced

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

CEO & Director exercised options and sold UK£2.3m worth of stock

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

Upcoming dividend of UK£0.16 per share at 3.5% yield

GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over

GSK's (LON:GSK) Solid Earnings Are Supported By Other Strong Factors

Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial

GSK plc to Report Q1, 2024 Results on May 01, 2024

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies